– USA, CA – Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Steven R. Loranger has been appointed to its board of directors. Loranger was most recently chief executive officer and president of leading global water technology company Xylem Inc., following his service as chairman, president and chief executive officer of ITT Corporation for seven years.
Prior to joining ITT, Loranger served as executive vice president and chief operating officer of Textron, Inc., and held executive positions at Honeywell International Inc. and its predecessor company, AlliedSignal, Inc.
“We are excited to welcome Steve to our board of directors, which will benefit from his decades of experience leading large, innovation-focused corporations,” said Michael A. Mussallem, Edwards’ chairman and CEO. “We look forward to his insights and global experience gained from service in a variety of highly regulated, high-tech industries with significant focus on quality.”
Currently, Loranger serves on the boards of directors of Xylem, Inc., the Smithsonian National Air and Space Museum and the Congressional Medal of Honor Foundation. He also served on the board of FedEx Corporation from 2006 to 2014.
A former U.S. Navy lieutenant, Loranger holds bachelor’s and master’s degrees from the University of Colorado.
About Edwards Lifesciences
Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.